Skip to main content
. 2023 Nov 16;30(11):1377–1389.e8. doi: 10.1016/j.chembiol.2023.07.011

Figure 3.

Figure 3

Distinctive antibody repertoire from the ASCs of an individual with a recent SARS-CoV-2 infection

(A) Depicts ELISA on donor (ADIRP0003238) serum showing binding to nucleocapsid, RBD, S2, and S1 proteins.

(B) ELISA binding to RBD, S2, S1, and Trimer (Tri.) proteins by antibodies selected for synthesis and screening from ADIRP0003238.

(C and D) (C) V-gene usage of selected antibodies, and (D) SHM in ADIRP0003238 donor’s ASC-derived monoclonal antibodies.

(E) Competitive ELISA screening of antibodies for ACE2/RBD blockade shown as % blockade.

(F) Pseudovirus neutralization screening of all antibodies expressed as recombinant IgG1. Target cells used were an ACE2/TMPRSS2-expressing cell line and all antibodies were tested at 10 μg/mL. Neutralizing antibodies indicated in blue. Also see Figure S1.